Get started
Author

Aitor Azkárate

Observed names: A Azkarate, A. Azkarate, A. Azkárate, Aitor Azkarate, Aitor Azkarate Martinez, Aitor Azkàrate Martínez, Aitor Azkárate Martínez, Azkarate, Aitor
Observed institutions: Hospital Universitario Insular de Gran Canaria, Hospital Universitario La Paz, Hospital General Universitario Morales Meseguer, Marqués de Valdecilla University Hospital, Hospital General Universitario de Elche, Health Research Institute of the Balearic Islands, Hospital Universitario Central de Asturias, Instituto Murciano de Investigación Biosanitaria, Hospital Universitario Son Espases, Universidad de Murcia
ORCID: 0000-0002-6805-158X
Observed ORCID: 0000-0002-6805-158X
OpenAlex ID: A5064158750
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry
2017 · on behalf of the AGAMENON study group, Paula Jiménez Fonseca, et al. · British Journal of Cancer · 107
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
2025 · Fabrice Barlesi, Wenxiu Yao, et al. · The Lancet · 81
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
2024 · Tony S. K. Mok, Wenxiu Yao, et al. · Journal of Clinical Oncology · 79
PDF
Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry
2018 · Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, et al. · European Journal of Surgical Oncology · 59
Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab
2017 · on behalf of the AGAMENON study group, A Custodio, et al. · British Journal of Cancer · 50
Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients
2020 · Patricia Mondelo-Macía, Carmela Rodríguez-López, et al. · Cells · 28
PDF
Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer
2019 · Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, et al. · Thrombosis and Haemostasis · 27
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
2020 · Almudena Cotes Sanchís, Javier Gallego, et al. · PLoS ONE · 24
PDF
Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer
2016 · Paula Jiménez-Fonseca, Alberto Carmona-Bayonas, et al. · Gastric Cancer · 24
PDF
On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry
2016 · Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, et al. · Journal of the National Comprehensive Cancer Network · 22
PDF
Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry
2017 · AGAMENON study group, A. Carmona-Bayonas, et al. · Gastric Cancer · 20
PDF
New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA
2017 · Elena Duréndez-Sáez, Aitor Azkárate, et al. · Journal of Thoracic Disease · 19
PDF
Detection of the EGFR G719S Mutation in Non-small Cell Lung Cancer Using Droplet Digital PCR
2020 · Margalida Esteva-Socias, Mónica Enver-Sumaya, et al. · Frontiers in Medicine · 17
PDF
Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis
2017 · Laura Visa, Paula Jiménez-Fonseca, et al. · Journal of Geriatric Oncology · 17
Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis
2024 · Dolores Isla, Rosa Álvarez, et al. · Journal of Medical Economics · 10
PDF
Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry
2019 · the AGAMENON Study Group, A. Viúdez, et al. · Clinical & Translational Oncology · 10
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry
2021 · Felipe Alvarez-Manceñido, Paula Jimenez-Fonseca, et al. · Gastric Cancer · 9
PDF
External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
2020 · Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, et al. · Gastric Cancer · 7
PDF
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
2021 · Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, et al. · Therapeutic Advances in Medical Oncology · 6
Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain
2025 · Mariano Provencio, Manuel Cobo, et al. · The Lancet Regional Health - Europe · 4
First-line triplet or doublet chemotherapy for advanced gastric cancer: Analysis of 970 patients from a community practice registry
2016 · I. Echavarria Diaz-Guardamino, A. Carmona-Bayonas, et al. · Annals of Oncology · 4
PDF
A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations
2024 · Guillermo Suay, Paloma Martín-Martorell, et al. · Clinical & Translational Oncology · 3
Sotorasib in Advanced KRAS G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS Metastases
2026 · Silvia Novello, Natalie Maimon Rabinovich, et al. · JTO Clinical and Research Reports · 2
PDF
79TiP Progress of a phase I trial (TOTEM) of repotrectinib in combination with osimertinib in advanced, metastatic EGFR mutant NSCLC
2023 · A. Aguilar, M. Cobo, et al. · Journal of Thoracic Oncology · 2
PDF
Applying clinical natural language processing to lung cancer in Spain: a terminology-based panel approach
2026 · A. Ospina-Serrano, A. Azkárate, et al. · ESMO Real World Data and Digital Oncology · 1
Works count: 62
Citation count: 636
H-index: 14
I10-index: 16
Year
Topic
Type